《盈警響號》維他奶(00345.HK)料上半年錄介乎5,000萬元虧損至6,000萬元溢利
維他奶(00345.HK)預期,截至2021年9月30日止六個月期間,將錄得介乎5,000萬元虧損至6,000萬元溢利,與去年同期溢利約6.72億元相比,減少約91%至107%。此跌幅主要是由於在2021/2022財政年度第二季的市場需求大幅下跌。
維他奶指,在2021年7月2日,一份包含不恰當內容而且未經授權的內部備忘錄在社交平台被廣泛流傳,導致中國內地消費者對集團構成負面影響,以致在整個7月份內,中國內地不同銷售渠道均發生產品下架的情況。儘管公司的產品逐漸在部份渠道開始重新上架,但預計在夏天旺季的銷售損失將對集團截至2021年9月30日止六個月的收入和盈利產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.